News
Delix Therapeutics completes dose study for DLX-001
Delix Therapeutics – a company developing novel neuroplasticity-promoting therapeutics – has announced that it has completed dosing among first cohort of subjects. I
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Delix Therapeutics – a company developing novel neuroplasticity-promoting therapeutics – has announced that it has completed dosing among first cohort of subjects. I